Trial reportBone marrow transplantation2013
Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD.
Trial report in Bone marrow transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02177760 (Sirolimus in Prevention of aGVHD in Maternally Engrafted), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT)
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation.Scientific reports · 2021Trial
- Increased Foxp3Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Trial
- Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.International journal of clinical and experimental pathology · 2015Trial
- Cell Therapy as a Way to Increase the Effectiveness of Hematopoietic Stem Cell Transplantation.Cells · 2024Review
- Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD.Cell reports. Medicine · 2023Article
- The absence of AhR in CD4Clinical epigenetics · 2022Article
- Regulatory T Cells in GVHD Therapy.Frontiers in immunology · 2021Review
- Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells.Leukemia · 2020Article
- Therapeutic use of regulatory T cells for graft-versus-host disease.British journal of haematology · 2019Review
- Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?Biomarker research · 2019Review
- Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population.International journal of hematology · 2018Article
- Article
- Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Therapeutic advances in hematology · 2018Review
- Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Bone marrow transplantation · 2017Review
- Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation.International journal of hematology · 2017Article
- Article
- Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Journal of blood medicine · 2017Review
- Article
- Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation.American journal of translational research · 2017Article
- A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.Haematologica · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute GVHD (aGVHD) is a major obstacle to allogeneic hematopoietic SCT (alloHSCT). Although it is thought that aGVHD is initiated in secondary lymphoid organs at a very early stage of alloHSCT, whether CD4(+)FOXP3(+) regulatory T-cells (Tregs) have an impact on aGVHD development during this period remains unclear. Here, we measured Tregs in peripheral blood as early as possible after HLA-mismatched alloHSCT, and assessed the incidence of aGVHD. Flow cytometric analyses revealed that at the second week after HSCT, patients with aGVHD had significantly (P=0.018) lower Treg:CD4(+)T-cell ratios than those without aGVHD. As these differences were seen before the development of aGVHD, these ratios can predict the incidence of aGVHD. The cumulative incidence of aGVHD in patients with ratios of <9% was significantly higher than that in patients with ratios of 9% (P=0.0082, log-rank test). Additionally, the specific ratio of Tregs:CD4(+)T-cells was the most significant value among all other possible lymphocyte-associated ratios and absolute cell counts. These findings suggest that the ratio of Tregs:CD4(+)T-cells at the second week post HLA-mismatched alloHSCT might be a potent predictor of aGVHD in these patients. The practical efficacy of this finding should be verified in further interventional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.